Note 5 - Related Party Transactions (Details Textual) - USD ($)	1 Months Ended	3 Months Ended			6 Months Ended
	Mar. 31, 2021	Jun. 30, 2021	Mar. 17, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2020	Dec. 31, 2020	Sep. 30, 2020	Apr. 28, 2020	Nov. 26, 2019	Dec. 31, 2018	Apr. 16, 2018	Mar. 31, 2017
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total		$ (4,672,000)		$ (6,510,000)	$ (7,203,000)		$ (11,253,000)
Assets, Current, Total		16,077,000			16,077,000			$ 15,298,000
Liabilities, Current, Total		$ 11,911,000			11,911,000			$ 6,143,000
Interest Paid, Excluding Capitalized Interest, Operating Activities					2,202,000		2,031,000
Amortization of Debt Discount (Premium)					$ 1,815,000		1,257,000
Boyalife Asset Holding II [Member] | Convertible Debt [Member]
Debt Instrument, Interest Rate, Stated Percentage		22.00%			22.00%			22.00%
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 1.80			$ 1.80			$ 1.80				$ 1.80	$ 16.10
Boyalife Asset Holding II [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity														$ 10,000,000
Long-term Line of Credit, Total										$ 10,000,000
Debt Instrument, Interest Rate, Stated Percentage								22.00%
Interest Paid, Excluding Capitalized Interest, Operating Activities			$ 2,082,000
Amortization of Debt Discount (Premium)		$ 827,000		729,000	$ 1,655,000		$ 1,276,000
Interest Expense, Debt, Excluding Amortization		556,000		$ 515,000	1,106,000	$ 957,000
Interest Payable		$ 1,106,000			$ 1,106,000			$ 2,082,000
ImmuneCyte and Shangai KDWinfo Technology Co. Ltd. [Member] | Boyalife’s Cellular Therapy Division [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)	12,000,000
ImmuneCyte [Member] | Boyalife’s Cellular Therapy Division [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)	500,000
ImmuneCyte [Member]
Equity Method Investment, Ownership Percentage		8.64%			8.64%				18.79%		20.00%
Dilution Gain from Equity Method Investments					$ 262,000
Equity Method Investment Accumulated Gain Loss					(428,000)
Income (Loss) from Equity Method Investments, Total					0
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total					599,000
Assets, Current, Total		$ 3,753,000			3,753,000
Liabilities, Current, Total		$ 2,013,000			$ 2,013,000
ImmuneCyte [Member] | HealthBanks Biotech [Member]
Equity Method Investment, Ownership Percentage									75.16%		80.00%
ImmuneCyte [Member] | Private Institution [Member]
Equity Method Investment, Ownership Percentage									6.05%